FDA approves first-of-a-kind intravesical drug delivery system for bladder cancer
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
List view / Grid view
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.
The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.
European Parliament's SANT Committee urges for greater control on medicine provisions to help strengthen security of supply.
First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.
And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.
The Route B notification pilot will expand the MHRA’s risk-proportionate approach and help prepare for a new modifications process under upcoming regulations.
RFK Jr hits Comirnaty, Spikevax and Nuvaxovid with revised approvals for ‘high risk’ individuals.
Revisions to the harmonised general chapter “Particulate Contamination (Q-09)” aim to improve pharmaceutical drug development.
While no other country has an identical scheme, analysis of the 2025 payment rate shows the UK is significantly behind comparable countries.
The paper explores recent guidance by the EMA and aims to help companies ensure their developments are efficient and effective for the forthcoming transition.
The drug is the first treatment for desmoid tumours to be approved in the region.
Disruption to traditional distribution channels is anticipated to hinder widespread adoption of the channel.